Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
INTERCEPT PHARMACEUTICALS, INC. (ICPT)
|
Add to portfolio |
|
|
|
| Price: |
$17.05
| | Metrics |
| OS: |
41.7
|
M
| |
|
|
| Market cap: |
$710
|
M
| |
|
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
| |
|
|
|
BVPS
|
$2.23
| |
7.63
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 285.7 | 260.8 | 234.0 | 252.0 | 179.8 | 131.0 | 25.0 | 2.8 |
| Revenue growth | 9.6% | 11.4% | -7.2% | 40.2% | 37.3% | 424.9% | 796.9% | 59.7% |
| Cost of goods sold | 1.0 | 1.2 | 2.4 | 4.2 | 2.5 | 1.4 | 0.0 | 0.0 |
| Gross profit | 284.7 | 259.5 | 231.6 | 247.8 | 177.3 | 129.6 | 25.0 | 2.8 |
| Gross margin | 99.7% | 99.5% | 99.0% | 98.3% | 98.6% | 99.0% | 100.0% | 100.0% |
| Selling, general and administrative | 176.3 | 177.5 | 260.5 | 317.4 | 255.5 | 273.7 | 273.6 | 119.2 |
| Research and development | 176.6 | 182.7 | 189.0 | 242.8 | 207.3 | 191.5 | 153.9 | 112.7 |
| EBIT | -68.2 | -100.7 | -217.9 | -312.4 | -285.5 | -335.6 | -402.5 | -229.2 |
| EBIT margin | -23.9% | -38.6% | -93.1% | -124.0% | -158.8% | -256.3% | -1613.3% | -8237.1% |
| Pre-tax income | -174.9 | -136.4 | -273.4 | -344.7 | -309.2 | -360.4 | -412.8 | -226.4 |
| Income taxes | -396.7 | -44.9 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 226.9% | 32.9% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -174.9 | -136.4 | -273.4 | -344.7 | -309.2 | -360.4 | -412.8 | -226.4 |
| Net margin | -61.2% | -52.3% | -116.9% | -136.8% | -172.0% | -275.2% | -1654.6% | -8139.1% |
| |
| Diluted EPS | ($5.17) | ($4.28) | ($8.29) | ($10.89) | ($10.86) | ($14.38) | ($16.74) | ($9.56) |
| Shares outstanding (diluted) | 33.8 | 31.9 | 33.0 | 31.7 | 28.5 | 25.1 | 24.7 | 23.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|